vimarsana.com

Page 11 - Biopharma Dive News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Allakos Cutting About 50% of Workforce, Abandons Lirentelimab Development After Failing Inflammatory Testings

Following the strategic restructuring, Allakos reported that Lirentelimab failed in its Phase II studies for atopic dermatitis and chronic spontaneous urticaria. Read more.

Kyverna sets plans for IPO in test of biotech enthusiasm

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.